TriSalus Life Sciences, Inc.
TLSI
$4.73
$0.368.24%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 39.64% | 53.41% | 49.52% | 45.50% | 46.21% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 39.64% | 53.41% | 49.52% | 45.50% | 46.21% |
| Cost of Revenue | 44.80% | 69.75% | 85.04% | 80.65% | 58.79% |
| Gross Profit | 38.78% | 50.77% | 44.26% | 40.55% | 44.29% |
| SG&A Expenses | 15.41% | 15.15% | 14.11% | 11.88% | 9.17% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 13.99% | 9.91% | 2.45% | -8.44% | -13.16% |
| Operating Income | 11.92% | 25.49% | 27.08% | 36.00% | 38.41% |
| Income Before Tax | -0.37% | -30.56% | 28.78% | 42.90% | 57.64% |
| Income Tax Expenses | -25.00% | 16.67% | -25.00% | -118.18% | -52.94% |
| Earnings from Continuing Operations | -0.36% | -30.56% | 28.78% | 42.91% | 57.64% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -0.36% | -30.56% | 28.78% | 42.91% | 57.64% |
| EBIT | 11.92% | 25.49% | 27.08% | 36.00% | 38.41% |
| EBITDA | 11.72% | 25.69% | 27.43% | 36.53% | 39.05% |
| EPS Basic | -22.12% | -34.07% | 21.26% | 55.11% | 97.07% |
| Normalized Basic EPS | 50.62% | 39.03% | 48.83% | 68.45% | 95.48% |
| EPS Diluted | -21.97% | -34.17% | 21.20% | 55.05% | 97.06% |
| Normalized Diluted EPS | 50.62% | 39.03% | 48.83% | 68.45% | 95.48% |
| Average Basic Shares Outstanding | 64.54% | 49.51% | 36.27% | 38.19% | 76.96% |
| Average Diluted Shares Outstanding | 64.54% | 49.51% | 36.27% | 38.19% | 76.96% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |